market perform
reason report
upgrad new king diversifi durabl
bottom line upgrad outperform
stock sell intra-day loss valu
exceed valu premium offer put
allergan valu prior announc suggest investor
assum less effect steward allergan
asset cash flow cash allergan seem unlik
us base new dividend yield sustain
like growth dividend least high
probabl extract even synergi allergan
suggest yesterday upgrad outperform
maintain recent target price stock prior
compani model unchang pro forma model
combin compani assum achiev synergi outlin
compani call yesterday support valuat mid
rang combin compani even pessimist valuat
assumpt compani convinc investor cash flow
grow rather declin beyond mid stock
could offer consider upsid even current target price
believ multipl way investor win
yesterday discount valuat deal fall apart stock
like re-trac valu loss yesterday deal assum
littl opportun either compani pipelin futur capit
alloc synergi could easili exceed disclos abbvi
yesterday skill commerci hand product revenu
could easili exceed expect even none opportun
materi still see combin compani deliv sustain
pro forma ep revenu
investor assum worst humira
product fail grow impli revenu multipl
ep multipl justifi vivew new abbvie-allergan
combin entiti abl achiev anyth better current sector-
low multipl stock offer consider upsid risk
upgrad includ possibl allergan transact doesnt
close case stock like retrac valu loss
yesterday one key element combin compani
forecast suffer setback seem bigger risk abbvi
side upadacitinib label humira eros allergan
alway possibl otherwis see limit risk abil
complet transact low probabl disrupt defect
disappoint critic legaci franchis immunolog
aesthet drive perform combin compani
net debt total capit
price-to-earnings lt ep growth
averag dcf price-to-earnings p/sale
year price history/av daili volume mil
compani inform svb leerink llc research
revenu mm dilut ep includ option expens present
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
price target per share stock rate outperform
establish independ pharmaceut compani transit new
phase term scale oper effici plan acquisit allergan earli
allergan bring new revenu market categori outsid
current product portfolio allergan aesthet busi one endur franchis
industri unlik advers affect mani risk face tradit
necessarili fan consolid sake see bring
disciplin decis allergan portfolio confid maxim
valu allergan aesthet busi cash flow without disrupt effect
busi unit innov cultur commerci effect ad allergan
dilut abbvi exposur humira posit offer compani
signific opportun oper effici synergi alreadi
disclos face mani challeng humira franchis rebat reform patent
challeng biosimilar pathway chang patent reform product cash flow
seem rel secur beyond two cornerston hematolog busi
grow strongli sever year least emerg combin neurosci portfolio
gener signific revenu posit cash flow earli import
pipelin program combin compani come upadacitinib skyrizi venclexta
imbruvica new indic signific increment opportun probabl
allergan neurolog migrain psychiatri schizophrenia program boost
back indic compani long sinc abandon see combin
compani deliv mid-singl digit revenu growth high singl digit ep
growth offer investor attract low doubl digit dividend growth dividend yield
today regard portfolio particularli innov today
view stock compel trade vehicl mid reason post deal
valuat rang
deal
acquisit consist cash stock cash portion fund
current cash plu substanti new debt indic issu
estim new share allergan sharehold transact estim
total net debt leverag ratio net debt/ebitda
indic expect transact close first part
anticip signific ftc issu obstacl materi divestitur
identifi major product overlap allergan aesthet ophthalmolog busi
larg addit exist busi key pipelin program
migrain schizophrenia increment rather overlap
break-up fee allergan part deal valu part event
termin due failur obtain anti-trust approv requir pay allergan
combin compani
combin allergan much larger compani annual sale
estimate nearli flat compar revenu two compani compani
initi employe come allergan
accord slide basi result leapfrog
industri term sale industri pro forma basi two compani
oper margin approxim synergi state synergi
oper expens mainli allergan two compani pro forma
oper margin good better current
combin compani strong franchis immunolog hematolog aesthet
signific secondari franchis virolog hcv neurolog psychiatri gastrointestin
ophthalmolog women health
main franchis humira imbruvica mavyret botox combin compani
lead top better player secondari franchis deliv signific on-going
cash flow contribut suggest deliv industri lead oper cash
flow combin oper beat even larger compani novarti
outlook combin compani futur
use consensu estim combin allergan/abbvi aa total revenu
grow use svb leerink estim porg team
goodman team allergan forecast revenu grow
combin compani like revenu compound-annual-growth-rate
period compani revenu mix like immunolog oncolog
aesthet exhibit mix like shift immunolog
oncolog aesthet exhibit
pipelin synergi opportun limit
import program pipelin next gener medicin
immunolog inflammatori diseas medicin skyrizi/risankizumab upadacitinib
larg de-risk skyrizi alreadi approv upadacitinib await approv
import opportun includ new indic venclexta imbruvica orilissa
beyond program regard pipelin rel bare rova rest
oncolog program limit potenti prospect ad allergan portfolio
actual boost late stage portfolio bring allergan neurolog migrain
psychiatri schizophrenia program notwithstand comment call yesterday
expect compani move forward abicipar ultim abandon program
unless favor treat unforese reason regulatori agenc
affect abbvi portfolio
quit explicit use transact re-cycl expect near term
cash flow humira buy longer term cash flow allergan product mainli
aesthet franchis aesthet franchis revenu allergan
revenu faster grow part allergan portfolio appear
believ aesthet franchis especi botox includ cosmet therapeut
would provid combin compani durabl cash flow beyond
merger acceler diversif away humira
base analysi svbl consensu estim allergan clear
transact significantli reduc depend humira humira contribut
abbvi overal sale oper cash flow enterpris valu decreas materi post-
allergan estim prior transact humira contribut
overal revenu declin exhibit estim line
consensu estim forecast similar contribut declin
forecast declin humira revenu contribut coincid
expect loss-of-exclus
assum transact close humira share newco revenu declin
pre-merg post-merg product import
compani revenu mix fall previous post allergan reduct
import similar compani cash flow cash flow contribut
humira declin exhibit percentag entir compani
enterpris valu humira decreas today post close thu
lower valu contribut humira total entiti valu exhibit
exhibit humira overal sale svb leerink estim vs consensu
overal sale svbl consensu humira sale pre-merg svbl humira sale pre-merg consensu humira sale post-merg svbl humira sale post-merg consensu humira loe inc
exhibit humira estim oper flow
exhibit humira estim enterpris valu mn
oper flowshumira oper cf pre-mergerhumira oper cf post-mergerhumira loe enterpris valu mn humira share evnon-humira share ev inc
mean abbvi dividend
one highest dividend yield biopharmaceut sector
even overal market indic call expect maintain continu
grow dividend current level compani histor deliv
dividend commit dividend grow everi year sinc compani spun
dividend per share grow compound-annual-growth-rate pro-
forma combin compani model see reason compani cant achiev least
doubl digit dividend growth dividend outlook beyond depend ultim
rate eros humira us well defens aesthet
ophthalmolog franchis abbvi long term revenu forecast particularli
reliabl past suspect vulner neg revis nevertheless
still view dividend outlook stabl posit increment synergi posit
revenu perform backstop compani dividend pay-out least
mean abbvi leverag profil
transact estim combin abbvie-allergan total debt
approxim debt/ebitda ratio ratio among highest
biopharmaceut industri come year base
compani guidanc yesterday conceiv compani could de-lev even faster
schedul given expect cash flow combin entiti
abbvi valu loss exce premium paid allergan
prior announc offer enterpris valu
allergan ev announc ev declin
allergan increas expect allergan stock fulli close
spread deal price would brought stock price ev
exhibit valu loss exceed premium includ offer
price allergan suggest investor believ allergan asset worth less
abbvi hand market previous over-valu allergan
product either way believ neg reaction excess expect valu
recov investor get comfort transact new
profil outlook
feel transact
overal surpris find view larg transact posit part view
inform sell-off stock yesterday posit view mostli base
effect transact make diversifi compani less depend
humira manag team explain transact take near term secur
cash flow compani given credit deploy secur longer
term secur cash flow expect investor ultim valu transact
take advantag favor reimburs environ aesthet product
leverag abbvi still healthi credit rate borrow capac there noth excit
pipelin scientif strateg standpoint least term scientif clinic
combin synergi make sound financi valuat sens us
importantli run pro forma model assum expens save realiz
suggest manag think find justifi
current target price combin compani pessimist assumpt
termin cash flow growth rel earn revenu multipl assumpt
make explain stock price yesterday announc frankli ridicul
forward year revenu forward year ep termin cash flow growth
price target base simpl averag three approach
believ reason basi valu stock today approach use rock-bottom
assumpt long term cash flow growth post rel ep multipl pro
forma ep revenu multipl revenu appli peer ep revenu
multipl use averag larg cap larg molecul therapeut compani mid-term
growth tail risk celg averag consensu ep
multipl appli current ep estim give valu
use revenu multipl similar compani consensu sale
appli revenu estim give valu lastli
dcf valuat given wacc termin cash flow growth rate begin
humira biosimilar entri give present valu averag three
method current price target target price assumpt differ pro
forma combin abbvie-allergan model even pessimist assumpt
combin compani pro forma model give us year target price mid
risk view outlook valuat includ major chang price
outlook reimburs coverag label competit posit humira
compani late stage pipelin program upadacitinib risk includ
commerci develop disappoint compani oncolog product imbruvica
venclexta expand hematolog malign remain highli depend
commerci govern payer product chang govern payment
price polici could advers affect outlook lastli believ investor like warm
opportunist acquisit allergan increas risk allergan aesthet
busi product concern remain pipelin could weigh abbvi
stock immedi futur earli stock like influenc
sentiment humira botox likelihood complet allergan acquisit
pipelin phase later
pipelin phase later
million
svb leerink llc research compani file
million
good sold
 total revenu
sg total revenu
svb leerink llc research compani file
brand chemic name
type event
event trial detail
date known
specifi
up/down
svb leerink view
cll trial front-lin cll
phase trial reuslt newly-diagnos
supplementari approv cll result front-
phase trial front-lin aml
svb leerink llc research compani file
analysi stock price svb leerink target
method price base current larg cap hc stock mid-term growth tail risk
ep multipl appli ep celg
svb leerink forma ep estim
method present valu base price sale multipl peer larg cap biopharma stock
averag price sale larg cap biopharma multipl
impli market cap mm estimate sale
anticip share count mm
method leerink probabl adjust dcf adjust net wacc termin
current svb leerink dcf marketed/l stage program
sourc svb leerink llc estim compani file factset
